These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10984724)

  • 1. Reboxetine in the maintenance therapy of depressive disorder in the elderly: a long-term open study.
    Aguglia E
    Int J Geriatr Psychiatry; 2000 Sep; 15(9):784-93. PubMed ID: 10984724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial.
    Katona C; Bercoff E; Chiu E; Tack P; Versiani M; Woelk H
    J Affect Disord; 1999 Oct; 55(2-3):203-13. PubMed ID: 10628889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review.
    Burrows GD; Maguire KP; Norman TR
    J Clin Psychiatry; 1998; 59 Suppl 14():4-7. PubMed ID: 9818623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reboxetine in the treatment of depression in the elderly: pilot study.
    Andreoli V; Carbognin G; Abati A; Vantini G
    J Geriatr Psychiatry Neurol; 1999; 12(4):206-10. PubMed ID: 10616869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder.
    Carvalhal AS; de Abreu PB; Spode A; Correa J; Kapczinski F
    J Clin Psychiatry; 2003 Apr; 64(4):421-4. PubMed ID: 12716244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression.
    Ferguson JM; Mendels J; Schwart GE
    Int Clin Psychopharmacol; 2002 Mar; 17(2):45-51. PubMed ID: 11890185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.
    Berzewski H; Van Moffaert M; Gagiano CA
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S37-47; discussion S71-3. PubMed ID: 9169309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study.
    Grassi L; Biancosino B; Marmai L; Righi R
    J Clin Psychiatry; 2004 Apr; 65(4):515-20. PubMed ID: 15119914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials.
    Stahl SM; Mendels J; Schwartz GE
    J Clin Psychopharmacol; 2002 Aug; 22(4):388-92. PubMed ID: 12172338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reboxetine: a review of antidepressant tolerability.
    Mucci M
    J Psychopharmacol; 1997; 11(4 Suppl):S33-7. PubMed ID: 9438231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
    Massana J; Möller HJ; Burrows GD; Montenegro RM
    Int Clin Psychopharmacol; 1999 Mar; 14(2):73-80. PubMed ID: 10220121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.
    Versiani M; Mehilane L; Gaszner P; Arnaud-Castiglioni R
    J Clin Psychiatry; 1999 Jun; 60(6):400-6. PubMed ID: 10401920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression.
    Scates AC; Doraiswamy PM
    Ann Pharmacother; 2000 Nov; 34(11):1302-12. PubMed ID: 11098346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.
    Versiani M; Amin M; Chouinard G
    J Clin Psychopharmacol; 2000 Feb; 20(1):28-34. PubMed ID: 10653205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of reboxetine in depressive patients treated in routine clinical practice.
    Messer T; Schmauss M; Lambert-Baumann J
    CNS Drugs; 2005; 19(1):43-54. PubMed ID: 15651904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
    Nelson JC; Portera L; Leon AC
    J Clin Psychiatry; 2005 Nov; 66(11):1409-14. PubMed ID: 16420078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
    Versiani M; Cassano G; Perugi G; Benedetti A; Mastalli L; Nardi A; Savino M
    J Clin Psychiatry; 2002 Jan; 63(1):31-7. PubMed ID: 11838623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reboxetine, the first selective noradrenaline reuptake inhibitor antidepressant: Efficacy and tolerability in 2613 patients.
    Versiani M
    Int J Psychiatry Clin Pract; 2000; 4(3):201-8. PubMed ID: 24927454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reboxetine: a preliminary report on its use through the Special Access Program.
    Kennedy SH; Lam RW; Cohen NL; Rosenbluth M; Sokolov ST; McIntyre RS; Chue P; Craigen G;
    J Psychiatry Neurosci; 2002 Nov; 27(6):418-22. PubMed ID: 12491574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.